InMed Pharmaceuticals Inc.
INMDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
INM-755 (cannabinol) cream | Phase 2 | Epidermolysis Bullosa Simplex | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in InMed Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in InMed Pharmaceuticals Inc.'s (INM) pipeline across Phase 2. Its lead program is INM-755 (cannabinol) cream (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is InMed Pharmaceuticals Inc.'s next FDA catalyst?→
InMed Pharmaceuticals Inc.'s (INM) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INM biotech catalysts?→
Add INM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow InMed Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.